00 days
00 hrs
00 mins
00 sec
Download Program
11 October
12 October
13 October
14 October




11 October

HALLS

HEMATOLOGY PROGRAM

 

 

13.50-14.00

OPENING REMARKS OF EHOC 2023 Birol Güvenç, Serdar Bedii Omay, Bülent Zülfikar, Giuseppe Saglio, Osman İlhan

 

 

14.00 - 14.20

Life Time Achivement Award Presentation: Influence of Women on Turkish Hematology

Chair: Birol Guvenç

Speaker: Deniz Sargın(Virtual)

 

 

14.20-15.20 

SESSION 1 - AML

CHAIRS: Zeba Aziz - Serdar Bedii Omay

 

 

14.20 - 14.30

State of the Art - Role of Maintenance Therapy in AML

Zeba Aziz

 

 

14.30 - 14.50

A Case of AML Given Maintanance Therapy

Mehmet Yılmaz

 

 

14.50 - 15.10

Induction Therapy Choices and Responses in a Third World Country: A Single Center Study From Pakistan

Amjad Zafar(Virtual)

 

 

15.10 - 15.20

Future Perspectives

Naval Daver(Virtual)

 

 

15.20 - 15.40

Life Time Achivement Award Presentation:

Chair:Gamze Tanrıöver

Speaker: Robert Peter  Gale

 

 
15.40-16.10

SATELLITE SYMPOSIUM

The Role of Lenalidomide in the Management of Multiple Myeloma in Light of Clinical Experiences and Future Directions

Chair:Mustafa Çetiner

Speaker:Tülin Tuğlular

 

 

 

 
16.10-16.40

POSTER WALK WITH COFFEE BREAK

Chair : Mehmet Hilmi Doğu

 

 

 

 

Biomedical Analysis of Red Blood Cells in Polycythemia Vera, Application of Raman Spectroscopy

Weronika Marzena Lebowa

 

 

The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients With Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-Center Real-Life Study

Müzeyyen Aslaner Ak

 

 

A Rare Cause of Cyanosis: Hemoglobin Kansas

Metban Mastanzade

 

 

A Rare Cause of Lymphadenopathy: Kikuchi Fujimoto

Gülcan Erbaş

 

 

16.40-18.00 

SESSION 2 - ALL

CHAIRS: Serdar Bedii Omay - Fevzi Altuntaş

   

16.40-16.50

State of the Art

Giovanni Martinelli(Virtual)

   

16.50-17.10

Patient 1 - Presentation and Discussion

Birol Güvenç

   

17.10-17.30

Elderly Ph+ Patient Sound Feasible?

Giovanni Marconi

   

17.30-17.50

When to Transplant

Sabina Chiaretti / Yes(Virtual) – Elias Jabbour / No (Virtual)

   

17.50-18.00

Future Perspectives

Elias Jabbour(Virtual)

   

17.00-18-50 

SESSION 3 - SELECTED ORAL COMMUNICATIONS (ADULT HEMATOLOGY)

CHAIRS: Giuseppe Saglio -Osman İlhan

18.00-18.10

Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients With Relapsed Multiple Myeloma (Ikema): Final Overall Survival Analysis

Ecenur Güder Arslan

18.10-18.20

Increased Carotid Intima Media Thickness As an Indicator of Increased Cardiovascular Risk in Patients With Primary Familial Erythrocytosis

Alpay Yeşilaltay

18.20-18.30

New Molecular Targets in Cancer Cell Bioenergetic Pathways

Ivan Tyumin

18.30-18.40

Changes in Mucosa-Associated Invarıant T Cells (Maıt), Associated Cytokines, and Mr-1+ Cell Number and Phenotype in the Peripheral Blood of Pediatric ITP Patients With and Without Eltrombopag Therapy

Ekrem Ünal




12 October

HALLS

HEMATOLOGY PROGRAM

 

 

08.15-08.45

ORAL COMMUNICATIONS SESSIONS  (ADULT HEMATOLOGY)

Chairs: Emin Kaya - Mehmet Ali Uçar

08.15-08.25

Evaluation of Vitamin D Status in Adult Patients With Immune Thrombocytopenia

Rafiye Çiftçiler

 

 

08.25-08.35

The Role of Adamts13 Activity Levels on Disease Exacerbation or Relapse in Patients With Immune-Mediated Thrombotic Thrombocytopenic Purpura: Post Hoc Analysis of The Phase 3 Hercules and Post-Hercules Studies

Özgüç Semih Şimşir

 

 

08.35-08.45

Ureteral Amyloidosis: A Case Report of Successful Management With Surgery, Radiation, and Chemotherapy

İbrahim Halil Açar(Virtual)

 

 

09.00-10.00

ADULT & PEDIATRIC ONCOHEMATOLOGY JOINT (BMT VS CAR T CELL)

CHAIRS: Khalid Halahleh - Oral Nevruz

 

 

09.00-09.10

State of the Art

Arnon Nagler(Virtual)

 

 

09.10-09.30

Is Hematopoietic Stem Cell Transplantation Necessary to Consolidate Hematological Remission After CAR-T Therapy?

Francesco Saglio

 

 

09.30-09.50

Post CAR-T: To Transplant, or Not To Transplant, That’s The Question!

Koray Yalçın

 

 

09.50-10.00

Future Perspectives

Fatma Visal Okur

 

 

10.00-11.00

ADULT & PEDIATRIC HEMATOLOGY ON HEMOGLOBINOPATHIES JOINT SESSION 

CHAIRS: Salam Al-Kindi - Fahri Şahin

 

 

10.00-10.10

State of the Art

Maria Capellini(Virtual)

 

 

10.10-10.30

A Patient Case on Non-Transfusion Dependent Thalassemia

Ali Taher (Virtual)

 

 

10.30-10.50

Patient 2 - Presentation and Discussion

Anıl Tombak

 

 

10.50-11.00

Future Perspectives

Salam Al-Kindi

 

 

11.00-11.30

 COFFEE BREAK

 

 

11.30-12.50

SESSION 4 - MM

CHAIRS: Claudio Cerchione - Evangelos Terpos(Virtual) - Tülin Tuğlular

 

 

11.30-11.40

How I Treat Relapsed Refractory Multiple Myeloma - CAR-T and Bispecific Antibodies

Claudio Cerchione

 

 

11.40-11.50

Mesurable Residual Disease(MRD) in the Era of Modern Therapies for the Treatment of Múltiple Myeloma

Roberto Magalhaes

 

 

11.50-12.05

A Case of MM With Extramedullary Plasmacytoma Involving Optic Chiasm

Alpay Yeşilaltay

 

 

12.05-12.20

Management of Late Relapse With T-Cell Engagers

Alessandra Romano(Virtual)

 

 

12.20-12.40

"Smoldering Myeloma” To Treat versus Not to Treat?

Evangelos Terpos (Virtual-No)- Claudio Cerchione (Yes)

 

 

12.40-12.50

Future Perspectives

Roberto Magalhaes

 

 
12.50-13.20
SATELLITE SYMPOSIUM
’’Ruxolitinib Experience in Myelofibrosis Treatment’
Chair: Mustafa Nuri Yenerel
Speaker: Elif Birtaş Ateşoğlu

 

 

13.20-14.20

LUNCH BREAK

 

 

14.20-14.40

Life Time Achivement Award Presentation: New Targeted Therapies in Acute Lymphoblastic Leukemia

Chair: Nilgün Sayınalp

Speaker: Dieter Hoelzer

 

 

14.40-16.00

SESSION 5 - CML

CHAIRS: Naeem Chaudhri -Pia Raanani(Virtual)– A.Emre Eşkazan

 

 

14.40-14.50

CML 2023 - State of the Art and Cutting Edge Issues

Pia Raanani(Virtual)

   

14.50-15.10

Young, Intolerant and Resistant

Carmen Fava(Virtual)

   

15.10-15.30

A Patient With Multipl TKI Failure

Deniz Özmen İbiş

   

15.30-15.50

Now that 2 gen TKIs are becoming generic, is still imatinib the best choice as first line therapy?

Giuseppe Saglio(Yes) - Tomasz Sacha(No)

   

15.50-16.00

Future Perspectives

Naeem Chaudhri

   

16.00-17.20

SESSION 6 - CLL

CHAIRS: Ahmad Ibrahim - Sevgi Kalayoğlu Beşışık

   

16.00-16.10

Treatment of CLL in 2023

Antonio Cuneo(Virtual)

   

16.10-16.30

Patient 1 - Presentation and Discussion

Argyris Symeonidis(Virtual)

   

16.30-16.50

Patient 2 - Presentation and Discussion

Fatma Eda Nuhoğlu Kantarcı

   

16.50-17.00

Combo Therapy

Ahmad Ibrahim

   

17.00-17.10

Mono Therapy

Gerardo Musuraca

   

17.10-17.20

Future Perspectives

Alessandra Ferrajoli(Virtual)

 

 

17.20-17.50

POSTER WALK WITH COFFEE BREAK

Chair: Hüseyin Saffet Beköz

   

Reaction of the Circulating Regulatory T Cells After Chemoradiation Therapy of Hodgkin Lymphoma

Angelika Melnikova

   

Infection Rates Across the Autologous Stem Cell Transplantation With Reflection of Multiple Myeloma Induction Story in Turkey

Simge Erdem

   

Characterization and Management of Patients With Hereditary Factor X Deficiency: A Retrospective Single Center Experience

Nigar Abdullayeva

   

Localized Al Amyloidosis of the Urinary Bladder Presenting With Painless Massive Hematuria

Kıvanç Koruk

   

Syndrome of Inappropriate Antidiuretic Hormone Secretion As Central Nervous System Lymphoma Relapse Sign of Nodal Diffuse Large B-Cell Lymphoma

Nur Seda İbili Çetinkaya

   

Development of Giant Plasmacytoma in a Patient With Bone Marrow Responce During Treatment: A Case Report

Rafiye Çiftçiler

   

SESSION 7 - MPN'S

CHAIRS: Tariq Mughal - Rajko Kusec - Gülsüm Özet

 

17.50-18.00

State of the Art

Tariq Mughal

 

18.00-18.20

Patient 1 - Presentation and Discussion

Alessandro Lucchesi(Virtual)

 

18.20-18.40

Patient 2 - Presentation and Discussion

Selami Koçak Toprak(Virtual)

 

18.40-19.00

First-Line Treatment Choice for a Young PV Patient - HU vs. IFN

Rajko Kusec - A. Emre Eşkazan

 

19.00-19.10

Future Perspectives

Danilla Cilloni

 

 




13 October

HALLS

HEMATOLOGY PROGRAM

 

 

08.10-08.50

ORAL COMMUNICATIONS SESSIONS  (ADULT HEMATOLOGY)

 Chair: Ferit Avcu

08.10-08.20

The Relatıonshıp Between Policytemia Vera and Metabolic Syndrome: The Single Center Experience

Cem Selim

 

 

08.20-08.30

The Outcome of Perıpheral T-Cell Lymphoma Patients Failing First-Line Therapy, From Prospective Cohort of T-Cell Brazil Project

Carmino De Souza(Virtual)

 

 

08.30-08.40

Global Research Patterns on Blood Donor Deferral: An Analysis of Themes, Trends, and Influence

Birol Güvenç

 

 

08.40-08.50

A Ghosal Hematodiaphyseal Dysplasıa Case: Excellent Response to Non-Sterodial Anti-Inflamatory Drug Treatment

Hasan Fatih Çakmaklı

 

09.00-10.00

SESSION 8 - Indolent NHL

CHAIRS: Burhan Ferhanoğlu - John Lister

 

 

09.00-09.10

Follicular Lymphoma

Burhan Ferhanoğlu

 

 

09.10-09.30

Follicular Lymphoma - Predicting Aggressive Behavior and Treatment Options

John Lister

 

 

09.30-09.50

Is There Any Role of SCT in the New Era of Treatment Follicular Lymphoma?

Murat Özbalak (No)                            
Sinem Civriz Bozdağ (Yes)

 

 

09.50-10.00

Future Perspectives

Stefano Luminari(Virtual)

 

 

10.00-10.20

Life Time Achivement Award Presentation - Survival After Failing ELN Milestones

Chair : Orhan Ayyıldız Speaker: Rudiger Hehlmann

 

 
10.20-10.50

SATELLITE SYMPOSIUM
"Clinical Presentation of PNH"

Speakers:

Tayfur Toptaş(PNH Diagnosis and Treatment)

Anıl Tombak(PNH is an intravascular hemolysis disease)

 

 

10.50-11.20

 COFFEE BREAK

 

 

11.20-12.20

SESSION 9 - Aggressive NHL

CHAIRS: Umberto Vitolo - Olga Meltem Akay

 

 

11.20-11.30

State of the Art of The Treatment of Aggressive Lymphomas

Umberto Vitolo

 

 

11.30-11.50

Transformed Follicular Lymphoma

Elif Birtaş Ateşoğlu

 

 

11.50-12.10

Role of ASCT in Treatment of R/R Lymphoma Patients in Resource Limited Countries

Adriatik Berisha

 

 

12.10-12.20

Future Perspectives

Gerardo Musuraca

 

 

12.20-13.20 

SESSION 10 - HL

CHAIRS: Carmino De Souza(Virtual) – Leylagül Kaynar

 

 

12.20-12.30

Treatment of Classical Hodgkin Lymphoma

Carmino De Souza(Virtual)

 

 

12.30-12.50

Patient 1 - Presentation and Discussion

Shahla Shabanova

 

 

12.50-13.10

An Interim PET Positive Patient With Advanced Stage Hodgkin Lymphoma

Tayfur Toptaş

 

 

13.10-13.20

Future Perspectives

Irina Panovska(Virtual)

 

 

13.20-14.20

LUNCH BREAK

   

14.20-15.40

SESSION 11 - MDS

CHAIRS: Moshe Mittelman(Virtual) - Mustafa Çetiner

   

14.20-14.30

State of the Art

Moshe Mittelman(Virtual)

   

14.30-14.50

Optimizing the Management in Low Risk MDS

Uwe Platzbecker(Virtual)

   

14.50-15.10

Patient 2 - Presentation and Discussion

Mustafa Çetiner

   

15.10-15.30

Patient with Polycythemia, Thrombocytopenia and Bone Marrow Failure with A Familial Hematologic Disease

Moshe Mittelman(Virtual)

   

15.30-15.40

Future Perspectives

Guillermo Garcia Manero(Virtual)

   
15.40-16.10

IDEOGEN AG SATELLITE SYMPOSIUM
Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma with Pralatrexate and Belinostat

Chair: Giuseppe Gritti

Speaker:Ali Ünal(Clinical Outcomes and T-Follicular Helper Phenotype Response with Belinostat in PTCL)

 Speaker: Owen A.O’Connor(A 20-Year Journey into the Development of Pralatrexate: What's Next?)

   

16.10-16.30

Life Time Achivement Award Presentation: A 50 Year Personal Perspective on the Treatment of Acute Leukemia

Chair : Zafer Gülbaş

Speaker: Charles Schiffer

   

16.30-17.30

SESSION 12 - COAGULOPATHIES

CHAIRS: Drew Provan – Bülent Antmen

   

16.30-16.40

State of the Art

Drew Provan

   

16.40-17.00

Patient 1 - Presentation and Discussion

Bülent Antmen

 

 

17.00-17.20

Patient 2 - Presentation and Discussion

Defne Ay Tuncel

   

17.20-17.30

Future Perspective

Güray Saydam(Virtual)

 

 

17.30-18.00

POSTER WALK WITH COFFEE BREAK

Chair :Vahap Okan

 

 

Can Radiotherapy Induce a Clinical Response With Occasional Long-Term Remission In Recurrent Granulosa Cell Tumors of the Ovary?

Ibtehaj Taher Hassan

   

Azerbaijan Experience of Haemophilia Care.

Gunel Alizade

   

Autologous Hematopoietc Cell Transplantation (Hct) For Hodgkin Lymphoma, Real World Experience of a Single Center Experience.

Carmıno De Souza

   

A Phase 3 Study To Evaluate the Effıcacy and Safety of Caplacizumab Without First-Line Therapeutic Plasma Exchange in Adults With Immune-Mediated Thrombotic Thrombocytopenic Purpura

Özgüç Semih Şimşir

   

18.00-19.10 

SESSION 13 - RARE ENTITIES

CHAIRS: Hanan Hamed - Mustafa Nuri Yenerel

   

18.00-18.15

Clinical Case of Blastic Plasmacytoid Dendritic Cell Neoplasm BPDCN

Hanan Hamed

18.15-18.30

Clinical Case of Mastocytosis

Daniela Cilloni

18.30-18.45

Hereditary Hemolytic Anemias:Red Cell Membrane Defects New Insights

Achilles Iolascon(Virtual)

18.45-19.00

Clinical Case of PNH

Mustafa Nuri Yenerel

19.00-19.10

Discussion

All




14 October

HALLS

HEMATOLOGY PROGRAM

 

 

08.10-08.50

ORAL COMMUNICATIONS SESSIONS Chair: Ali Ünal

 

 

08.10-08.20

Long-Term Outcomes of Allogeneıc Stem Cell Transplantation For Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma: Multi-Center Experince From Turkey

Ayşe Uysal

 

 

08.20-08.30

Ibrutinib-Obinutuzumab Combination Therapy in the Treatment of Relapsed Nodal Marginal Zone Lymphoma: A Case Study

Nuray Gül Açar(Virtual)

 

 

08.30-08.40

Real-World (RW) Treatment Patterns and Outcomes in Patients (PTS) with Relapsed/Refractory Multiple Myeloma (RRMM) with at Least One Prior Therapy in Turkey

Özgür Pektaş

 

 

 09.00-10.00

SESSION 14 - SUPPORTIVE CARE

CHAIRS: Claudio Cerchione - Mustafa Çetiner -Mehmet Sönmez

 

 

09.00-09.15

Febrile Neutropenia

Şiran Keske

 

 

09.15-09.30

Anemia and Transfusion-Medicine

Birol Güvenç

 

 

09.30-09.45

Pain Management

Halil Çetingök

 

 

09.45-10.00

The “Problem” of Survivors: How to Manage Them and How to Monitor Long-Term Adverse Events

Ajai Chari(Virtual)

 

 

10.00-10.20

Life Time Achivement Award Presentation:

Chair:  Şehmus Ertop Speaker: Hagop Kantarjian(Virtual)

 

 
10.20-10.50
SATELLITE SYMPOSIUM
"Open a New Dimension in Multiple Myeloma Treatment with Darzalex"
Chair:Birol Güvenç
Speaker:Şebnem İzmir Güner

 

 

10.50-11.20

POSTER WALK WITH COFFEE BREAK

Chair : Demet Çekdemir

 

 

Cutaneous Richter Transformation in the 16th Year of Follicular Lymphoma Diagnosis

Ulviyya Hasanzade

 

 

Retrospective Evaluation of Bone Marrow Findings in Autoimmune Hemolytic Anemias

Eren Arslan Davulcu

 

 

Reactivation of Hepatitis B in a Patient With Untreated Chronic Lymphocytic Leukemia

Sinan Demircioğlu

 

 

Ibrutınıb Related Neuropathy: A Case Report

Zeynep Tuğba Güven

 

 

A Rare Intersection: Coexistence of Breast Cancer and Sickle Cell Disease in A 40 - Year-Old Female - A Case Report

İdil Yürekli

   
11.20-11.50
SATELLITE SYMPOSIUM
"Reblozyl changes the blood transfusion needs for patients with beta thalassemia and MDS "
Chair:Birol Güvenç
Speakers: Mustafa Çetiner - Bülent Antmen
   

11.50-12.40

SESSION 15 - BONE MARROW FAILURE

CHAIRS: Ahmad Ibrahim – Işık Kaygusuz

Atagündüz

   

11.50-12.10

Aplastic Anemia

Régis Peffault de Latour (Virtual)

   

12.10-12.30

Severe Aplastic Anemia

Ahmet Mert Yanık

   

12.30-12.40

Future Perspectives

Régis Peffault de Latour

12.40-13.00

Life Time Achivement Award Presentation- Key Factors For the Success of Clinical Research Networks in Myeloproliferative

Chair : Siret Ratip

Speaker: Tiziano Barbui

13.00-14.00

LUNCH BREAK

14.00-15.30 

SESSION 16 - CELLULAR THERAPY

CHAIRS:Jean François Rossi– Elif Birtaş Ateşoğlu

14.00-14.20

The Future of Cell Therapy of Haematologic Cancers

Robert Peter Gale

14.20-14.40

A Pivotal Study Report of CNCT19 (Inaticabtagene Autoleucel) Treatment in Adult R/R B-cell ALL in China.

Lv Lulu (Virtual)

14.40-15.00

Dendritic Cells in Oncology

Angelika Melnikova

15.00-15.10

Stem Cell Transplantation in Solid Oncology. A Clinical Case

Anastasia Mamonova

15.10-15.25

Adoptive Immunotherapy in Oncology

Lyudmila Grivtsova

15.25-15.30

Conclusions

Jean François Rossi

 15.30-16.45

SESSION 17 - AI IN MEDICINE

CHAIRS: Moshe Mittelman(Virtual) – Mehmet Ali Özcan

15.30-15.40

Introductory Presentation

Moshe Mittelman(Virtual)

15.40-16.00

The Application of AI to Thrombocytopenia

Drew Provan

16.00-16.30

CPi-Clalit Proactive and Preventative Intervention

Doron Netzer(Virtual)

16.30-16.45

Discussion

All

16.45

CLOSING REMARKS OF EHOC 2023